NewAmsterdam Pharma stock slides on insider sale notices — what investors watch next for NAMS
NewAmsterdam Pharma shares fell about 5% to $33.42 in afternoon trading Monday after two insiders filed Form 144 notices for proposed stock sales tied to RSU vesting. CFO M. Ian Somaiya and CSO Johannes Kastelein flagged plans to sell a combined 11,118 shares. The stock touched an intraday low of $32.68. Biotech stocks broadly lagged the market ahead of Friday’s U.S. jobs report.